{"id":"W2969017474","doi":"10.1634/theoncologist.2019-0321","title":"A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229)","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University of British Columbia; University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Durvalumab; Trastuzumab; Internal medicine; Metastatic breast cancer; Oncology; Breast cancer; Clinical endpoint; Pertuzumab; Cancer; Response Evaluation Criteria in Solid Tumors; Adverse effect; Progressive disease; Chemotherapy; Gastroenterology; Clinical trial; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008162417,0.0008008121,0.001364538,0.0002594752,0.0003059466,0.0005612214,0.0007202601,0.0006057755,0.002754938],"category_scores_gemma":[0.0003906405,0.0003009401,0.0004690912,0.000285516,0.0004809643,0.0003045445,0.0002528623,0.001549397,0.0005763829],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008826185,"about_ca_system_score_gemma":0.00129603,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002037394,"about_ca_topic_score_gemma":0.006318848,"domain_scores_codex":[0.9997125,0.0001307237,0.00001370435,0.000039212,0.00002954316,0.00007419488],"domain_scores_gemma":[0.9997254,0.00003217906,0.00003515372,0.00001902772,0.00001520923,0.0001729186],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7198088,0.05747848,0.008352256,0.0007339321,0.0008218847,0.0005907738,0.0001942612,0.002560682,0.05440889,0.0004236566,0.009379202,0.1452472],"study_design_scores_gemma":[0.6340095,0.3416829,0.0129252,0.00004000471,0.000297196,0.0004124716,0.00003777202,0.00175192,0.004610789,0.0001666297,0.004040109,0.00002550353],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930012,0.001326133,0.0002187628,0.0003286692,0.00009312079,0.001893033,0.0006993411,0.00007715643,0.002362517],"genre_scores_gemma":[0.9927255,0.0009440473,0.0008011548,0.0004873369,0.0001248131,0.001092038,0.001654125,0.00001472982,0.002156185],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002754938,"threshold_uncertainty_score":0.00921613,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05384371908796651,"score_gpt":0.4257430872117402,"score_spread":0.3718993681237737,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}